For: | Huang X, Chen YT, Song HZ, Huang GC, Chen LB. Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 2011; 17(25): 3002-3011 [PMID: 21799646 DOI: 10.3748/wjg.v17.i25.3002] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v17/i25/3002.htm |
Number | Citing Articles |
1 |
Andreas R. de Biasi, Jonathan Villena-Vargas, Prasad S. Adusumilli. Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence. Clinical Cancer Research 2014; 20(21): 5384 doi: 10.1158/1078-0432.CCR-14-1298
|
2 |
Raghu Tadagavadi, Guofeng Gao, Wei Wang, Manuel Gonzalez, W. Reeves. Dendritic Cell Protection from Cisplatin Nephrotoxicity Is Independent of Neutrophils. Toxins 2015; 7(8): 3245 doi: 10.3390/toxins7083245
|
3 |
Xiaojun Huang, Qinghuan Ren, Leixiang Yang, Di Cui, Chenyang Ma, Yueliang Zheng, Junjie Wu. Immunogenic chemotherapy: great potential for improving response rates. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1308681
|
4 |
Martina Raudenska, Jan Balvan, Michaela Fojtu, Jaromir Gumulec, Michal Masarik. Unexpected therapeutic effects of cisplatin. Metallomics 2019; 11(7): 1182 doi: 10.1039/c9mt00049f
|
5 |
Haiping Song, Shujuan Liu, Ziyun Zhao, Weihong Sun, Xiaofang Wei, Xuezhen Ma, Peng Zhao, Daiqing Gao. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC. International Immunopharmacology 2017; 52: 197 doi: 10.1016/j.intimp.2017.09.014
|
6 |
Bernhard Englinger, Christine Pirker, Petra Heffeter, Alessio Terenzi, Christian R. Kowol, Bernhard K. Keppler, Walter Berger. Metal Drugs and the Anticancer Immune Response. Chemical Reviews 2019; 119(2): 1519 doi: 10.1021/acs.chemrev.8b00396
|
7 |
Zhijiang Wei, Guiying Liu, Rufu Jia, Wei Zhang, Li Li, Yuanyuan Zhang, Zhijing Wang, Xiyong Bai. Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells. Discover Oncology 2023; 14(1) doi: 10.1007/s12672-022-00535-9
|
8 |
Cuiling Zhou, Donglan Liu, Jie Li, Huanhuan Sun, Xiaobin Zheng, Shuncong Wang, Guobin Hong, Saradhi Mallampati, Hongliu Sun, Xiuling Zhou, Zhibin Cheng, Hongyu Zhang, Haiqing Ma. Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis. Oncotarget 2016; 7(52): 86500 doi: 10.18632/oncotarget.13394
|
9 |
Leilei Tao, Guichun Huang, Shujing Shi, Longbang Chen. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Medical Oncology 2014; 31(1) doi: 10.1007/s12032-013-0777-3
|
10 |
Cinzia Garofalo, Carmela De Marco, Costanza Maria Cristiani. NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.754541
|
11 |
Heena Sachdeva, Sukhbir Kaur. Cisplatin along with herbal drug treatment reduces the percentage of regulatory T cells and decreased the severity of experimental visceral leishmaniasis. Journal of Microbiology, Immunology and Infection 2018; 51(4): 435 doi: 10.1016/j.jmii.2017.03.001
|
12 |
Meenakshi Sharma, Rakesh Sehgal, Sukhbir Kaur, Timothy G. Geary. Evaluation of Nephroprotective and Immunomodulatory Activities of Antioxidants in Combination with Cisplatin against Murine Visceral Leishmaniasis. PLoS Neglected Tropical Diseases 2012; 6(5): e1629 doi: 10.1371/journal.pntd.0001629
|
13 |
Ya Hong Yuan, Chun Fang Zhou, Jiang Yuan, Li Liu, Xing Rong Guo, Xiao Li Wang, Yan Ding, Xiao Nan Wang, Dong Sheng Li, Han Jun Tu. NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells. Oncology Letters 2016; 12(5): 3167 doi: 10.3892/ol.2016.5112
|
14 |
Chiao-Jung Kao, Gregory T. Wurz, Arta M. Monjazeb, Daniel P. Vang, Timothy B. Cadman, Stephen M. Griffey, Michael Wolf, Michael W. DeGregorio. Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model. Cancer Immunology Research 2014; 2(6): 581 doi: 10.1158/2326-6066.CIR-13-0205
|
15 |
Rui-xian Han, Xu Liu, Pan Pan, Ying-jie Jia, Jian-chun Yu, Jian-Xin Gao. Effectiveness and Safety of Chemotherapy Combined with Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cells in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS ONE 2014; 9(9): e108958 doi: 10.1371/journal.pone.0108958
|
16 |
Lukasz Bialkowski, Alexia van Weijnen, Kevin Van der Jeught, Dries Renmans, Lidia Daszkiewicz, Carlo Heirman, Geert Stangé, Karine Breckpot, Joeri L. Aerts, Kris Thielemans. Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Scientific Reports 2016; 6(1) doi: 10.1038/srep22509
|
17 |
Xiang Huang, Shiyun Cui, Yongqian Shu. Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model. Immunologic Research 2016; 64(1): 160 doi: 10.1007/s12026-015-8734-1
|
18 |
Hosni A. Neweigy, Mona S. Gouida, Mohamed S. El Nagger, Mohamed L. Salem. Cancer micro-environment immune modulation by Egyptian cobra (Naja haje) crud venom. Egyptian Pharmaceutical Journal 2023; 22(2): 237 doi: 10.4103/epj.epj_156_22
|
19 |
Sharmilan Thanendrarajan, Young Kim, Ingo Schmidt-Wolf. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opinion on Biological Therapy 2012; 12(5): 565 doi: 10.1517/14712598.2012.668879
|
20 |
Ya-Wen Zheng, Run-Mei Li, Xin-Wei Zhang, Xiu-Bao Ren. Current Adoptive Immunotherapy in Non-Small Cell Lung Cancer and Potential Influence of Therapy Outcome. Cancer Investigation 2013; 31(3): 197 doi: 10.3109/07357907.2013.775294
|
21 |
Weimin Lin, Miao Chen, Le Hong, Hang Zhao, Qianming Chen. Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Frontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00532
|
22 |
Amir Sherif, Mudhar N. Hasan, Eva Radecka, Alvaro Lozano Rodriguez, Sarab Shabo, Mona Karlsson, Martin C. Schumacher, Per Marits, Ola Winqvist. Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. Scandinavian Journal of Urology 2015; 49(6): 453 doi: 10.3109/21681805.2015.1059880
|
23 |
Jun Ren, William R. Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, Pankaj Agarwal, Amy Hobeika, Erika Crosby, Zachary C. Hartman, Michael A. Morse, Kevin H. Eng, H. Kim Lyerly. Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. OncoImmunology 2017; 6(4): e1264563 doi: 10.1080/2162402X.2016.1264563
|
24 |
Xinxin Meng, Fengyun Ma, Dingli Yu. The diverse effects of cisplatin on tumor microenvironment: Insights and challenges for the delivery of cisplatin by nanoparticles. Environmental Research 2024; 240: 117362 doi: 10.1016/j.envres.2023.117362
|
25 |
Jing Chen, Xiang Huang, Guichun Huang, Yitian Chen, Longbang Chen, Haizhu Song. Preconditioning Chemotherapy with Cisplatin Enhances the Antitumor Activity of Cytokine-Induced Killer Cells in a Murine Melanoma Model. Cancer Biotherapy and Radiopharmaceuticals 2012; 27(3): 210 doi: 10.1089/cbr.2011.1116
|
26 |
G. Giaccone, L.A. Bazhenova, J. Nemunaitis, M. Tan, E. Juhász, R. Ramlau, M.M. van den Heuvel, R. Lal, G.H Kloecker, K.D. Eaton, Q. Chu, D.J. Dunlop, M. Jain, E.B. Garon, C.S. Davis, E. Carrier, S.C. Moses, D.L. Shawler, H. Fakhrai. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. European Journal of Cancer 2015; 51(16): 2321 doi: 10.1016/j.ejca.2015.07.035
|
27 |
Alec J. Kacew, Ethan J. Harris, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Jason I. Kass, Roy B. Tishler, Robert I. Haddad, Glenn J. Hanna. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology 2020; 105: 104676 doi: 10.1016/j.oraloncology.2020.104676
|
28 |
WenJia Wang, SiHao Qin, Lei Zhao. Docetaxel enhances CD3+ CD56+ cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation. Biomedicine & Pharmacotherapy 2015; 69: 18 doi: 10.1016/j.biopha.2014.10.026
|